{"organizations": [], "uuid": "c4bfe41d7f36ea3a5e79fcbaeae7f9c269ddc575", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-theravance-biopharma-says-fda-has/brief-theravance-biopharma-says-fda-has-approved-an-expanded-indication-for-trelegy-ellipta-idUSFWN1S20YC", "country": "US", "domain_rank": 408, "title": "BRIEF-Theravance Biopharma Says FDA Has Approved An Expanded Indication For Trelegy Ellipta", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-25T15:46:00.000+03:00", "replies_count": 0, "uuid": "c4bfe41d7f36ea3a5e79fcbaeae7f9c269ddc575"}, "author": "", "url": "https://www.reuters.com/article/brief-theravance-biopharma-says-fda-has/brief-theravance-biopharma-says-fda-has-approved-an-expanded-indication-for-trelegy-ellipta-idUSFWN1S20YC", "ord_in_thread": 0, "title": "BRIEF-Theravance Biopharma Says FDA Has Approved An Expanded Indication For Trelegy Ellipta", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "trelegy ellipta", "sentiment": "negative"}, {"name": "trelegy ellipta reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "theravance biopharma inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - Theravance Biopharma Inc:\n* THERAVANCE BIOPHARMA HIGHLIGHTS APPROVAL OF EXPANDED INDICATION IN THE US FOR ONCE-DAILY TRELEGY ELLIPTA FOR TREATMENT OF COPD PATIENTS\n* THERAVANCE BIOPHARMA INC - U.S. FDA HAS APPROVED AN EXPANDED INDICATION FOR TRELEGY ELLIPTA\n* THERAVANCE BIOPHARMA INC - EXPANDED APPROVAL IN U.S. ALLOWS TRELEGY ELLIPTA TO BE USED AS A TREATMENT FOR A BROADER POPULATION OF COPD PATIENTS Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-25T15:46:00.000+03:00", "crawled": "2018-04-25T16:11:49.000+03:00", "highlightTitle": ""}